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Apicomplexan parasites comprise a broad variety of protozoan parasites, including Toxoplasma gondii, Plasmodium, Eimeria, and
Cryptosporidium species. Being intracellular parasites, the success in establishing pathogenesis relies in their ability to infect a host-
cell and replicate within it. Protein palmitoylation is known to aﬀect many aspects of cell biology. Furthermore, palmitoylation has
recently been shown to aﬀect important processes in T. gondii such as replication, invasion, and gliding. Thus, this paper focuses
on the importance of protein palmitoylation in the pathogenesis of apicomplexan parasites.
1. Introduction
It is well known that unicellular eukaryotes are the simplest
models for the study of molecular mechanisms operating in
the whole domain. Apicomplexan parasites are a large group
of unicellular protozoan parasites, which include Toxoplasma
gondii, Plasmodium, Eimeria, and Cryptosporidium spp.
These parasites are the cause of great public health problems
aﬀecting both humans and animals [1]. These diseases have
high morbidity and mortality rates [2–4] and aﬀect about
one third of the global population. Toxoplasma gondii alone
is responsible for the infection of 2 billion people worldwide,
and the symptoms of toxoplasmosis are determined by
the immune status of the individual [5]. All members of
the phylum are characterized by the presence of a unique
organelle called apicoplast and an apical structure. Whereas
the apicoplast is involved in lipid metabolism [6–8], the
apical structure has a role in the invasion of the host-cell
(reviewed in [9, 10]).
Since most protozoa of the Apicomplexa phylum are
obligate intracellular parasites, host-cell invasion, replication
and egress are vital requirements for the establishment of
pathogenesis. The ability of the tachyzoite stage to invade,
replicate, and egress the host-cell repeatedly generating tissue
damage and inflammation is the basis of human and animal
symptoms. To date, the complex machinery involved in the
invasion process has been more or less characterized for
the diﬀerent members of the phylum [11]. Besides, it is
known that invasion of the host-cell is a highly coordinated
process and most of the proteins that participate in it
feature posttranslational modifications that regulate their
localization and/or function. Another contributing factor
to parasite dissemination is its capacity to replicate once
inside the host-cell. In fact, in T. gondii an increase in the
multiplication rate has been linked to the acute virulence in
mice [12, 13]. The replication process in T. gondii has been
thoroughly reviewed elsewhere [14, 15].
Posttranslational modifications add diversity to the
proteome. These dynamic modifications aﬀect almost all
aspects of cell biology and play an important role in
protein transport, cellular localization, and regulation of
enzymatic activity. Among these modifications we can find
glycosylation, alkylation, methylation, acetylation, phospho-
rylation, ubiquitination, and protein lipidation. Although
protein phosphorylation represents the vast majority of
regulated covalent modifications observed [16], the covalent
modification of proteins by lipids (protein lipidation) is an
emergent topic. Protein lipidation alters the physical and
functional properties of a protein, depending on the type of
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lipid attached to it. This functional diversity is provided by
four categories of protein lipidation: prenylation, glypiation,
cholesteroylation, and fatty acylation [17, 18]. With the
exception of cholesteroylation, all other lipidations have been
described to operate in apicomplexan parasites [19], and
some of them are even targets for the treatment of malaria
(recently reviewed in [20, 21]). Protein fatty acylation refers
to the covalent modification of proteins by fatty acids and
is divided into two categories: myristoylation and palmitoy-
lation [17]. Whereas myristoylation is the irreversible co-
or posttranslational attachment of myristic acid (C14 : 0)
onto proteins via a stable amide bond [22, 23], protein
palmitoylation is defined as the reversible posttranslational
attachment of palmitate (C16 : 0) via a thioester linkage [24].
Protein myristoylation has been reported in many apicom-
plexan parasites such as Eimeria tenella [25] and Plasmodium
falciparum [26, 27]. Although palmitoylation usually occurs
on a cysteine residue, less frequently it has also been shown to
occur onN-terminal amino acids via an amide bond [28, 29].
Palmitoylation is the only reversible lipidmodification and as
such, it can regulate the fate of the targeted proteins. In the
recent years, the study of posttranslational modifications and
more precisely protein palmitoylation has gained importance
in this group of protozoan parasites [30]. As such, in the
following sections of this paper we will focus on the role of
protein palmitoylation in diﬀerent processes involved in the
pathogenesis of apicomplexans.
2. Protein Palmitoylation
Our comprehension of protein palmitoylation and its func-
tion is based on studies in higher eukaryotes. A short
review of the most important roles of this posttranslational
modification is described below.
Palmitoylation is an important mechanism for regu-
lating subcellular localization [31, 32], traﬃcking (recently
reviewed in [33]), translocation to lipid rafts [34, 35],
regulation of enzymatic activity [36, 37], and gene expression
[38]. Before its attachment to the targeted protein, palmitate
must be activated in its coenzyme A derivative, palmitoyl-
CoA [39]. The reversible nature of this modification acts as
a molecular switch that dynamically controls and regulates
either the localization and/or function of selected proteins
[40, 41]. Besides, it is important to highlight that palmitoy-
lation does not have a clear sequence requirement other than
a cysteine residue.
Interestingly, palmitoylation is found both on peripheral
and transmembrane-spanning proteins. Integral membrane
proteins are palmitoylated in either their cytosolic domain
or at the transmembrane/cytosolic interface. In this type of
proteins, palmitoylation has been found to be aﬀected by
the proximity to the lipid-ordered phase of the membrane,
the composition of the transmembrane domain, and the
length of the cytoplasmic tail [42, 43]. Peripheral membrane
proteins that are palmitoylated are sometimes myristoylated
or prenylated as well. Myristoylation and prenylation occur
in the cytosol and confer transient membrane interaction
[44]. This transient association allows proteins to interact
with palmitoyl acyl-transferases (PATs), integral membrane
enzymes responsible for protein palmitoylation. Once palmi-
toylated, these proteins stably associate with membranes
[24, 44]. Members of the Ras superfamily of GTPases
are prenylated and some members are also palmitoylated
(reviewed in [33]). When palmitoylation is found with
myristoylation, the palmitoylated cysteine residue is usually
proximal to the N-terminal myristoylated glycine [22, 45].
Distinct from what occurs in integral membrane proteins,
the amino acids surrounding the palmitoylated cysteine
are not important when myristoylation takes place [45].
Members of the Src family of protein tyrosine kinases and Gα
are typical examples of this dual modification [46, 47]. When
palmitoylation is the only lipid modification, the modified
cysteine is usually located within the first 25 amino acids.
In this case, these proteins may possibly use an intrinsic
weak membrane aﬃnity for transient membrane interaction
before palmitoylation occurs [48, 49].
Regarding the mechanism underlying protein palmi-
toylation, it has been reported to occur either sponta-
neously or to be enzyme-mediated. Examples of spontaneous
palmitoylation are the mitochondrial proteins glutamate
dehydrogenase, carbamoyl phosphate synthetase 1, and
methylmalonate semialdehyde dehydrogenase where palmi-
toylation regulates their activities [36, 37, 50]. Recently,
protein palmitoylation of the mitochondrial protein 3-
hydroxy-3-methylglutaryl-CoA synthase has been shown
to play a role in gene regulation [38]. However, protein
palmitoylation is mainly enzyme-mediated either by DHHC-
containing proteins (Asp-His-His-Cys-containing proteins;
palmitoyl acyl-transferases; PATs) or membrane bound-O-
acyltransferase (MBOAT) proteins. Whereas intracellular
palmitoylation occurs by PATs, secreted proteins are palmi-
toylated by members of the MBOAT (membrane bound-
O acyl-transferase) family [51, 52]. Genes encoding DHHC
proteins are present in organisms from yeast to humans
[53, 54]. However, all these proteins have in general, some
shared characteristics such as having an even number of
transmembrane domains and to be expressed on the Golgi,
ER, and the PM [54, 55].
Depalmitoylation can occur in response to signals or
spontaneously [56]. In fact, an agonist-induced increase in
palmitate turnover has been observed for proteins such as H-
Ras [57], Gαs [58], endothelial nitric oxide synthase [59], and
PSD-95 [49]. Up to date, two lysosomal and one cytosolic
thioesterases are thought to mediate protein depalmitoyla-
tion. However, only the cytosolic acyl-protein thioesterase-
1 (APT1) has been reported to mediate depalmitoylation
in vivo. APT1 is a 29 kDa nonspecific thioesterase that can
remove fatty acyl groups from lysophospholipids as well as a
wide variety of proteins [60–62]. In a recent report, Yang and
colleagues showed that APT1 is palmitoylated, which may
tether this protein to the membrane and thus, facilitate the
depalmitoylation of its substrates [63]. The two lysosomal
hydrolases palmitoyl-protein thioesterase I (PPT1) and PPT2
do not remove palmitate groups from palmitoylated proteins
[64, 65] and as such, their substrates are unknown.
Among the functions of palmitoylation are the attach-
ment to membranes of otherwise soluble proteins and the
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traﬃc of lipid-modified proteins between diﬀerent compart-
ments. This sorting has been observed in the partitioning of
proteins into lipid rafts [34, 35, 66], ER-Golgi anterograde
traﬃc (reviewed in [67]), flagella [68, 69], and cilia [70,
71]. Another function of protein palmitoylation is the
regulation of protein activity. Palmitoylation has been shown
to regulate G-protein-mediated signaling at multiple levels: it
regulates both the localization and the transducing signal of
heterotrimeric G proteins (reviewed in [72]). Interestingly,
the enzymatic activity of N- and H-Ras proteins can be
blocked in vitro by using inhibitors, for example, small
molecules, targeting either a PAT type [73–75] or thioesterase
[76]. As such, these enzymes are arising as interesting new
targets for anticancer compounds. Mammalian and parasite
PATs are homologous in the cysteine rich-domain that
includes the DHHC motif but their N-and C-terminal ends,
which are thought to be responsible for either substrate
specificity or interaction with a possible regulator, are
completely diﬀerent. Thus, it will be interesting to see the
future development of PATs inhibitors capable of selectively
blocking the apicomplexan counterparts without aﬀecting
the human host.
3. Invasion in Apicomplexa
The eukaryotic phylum Apicomplexa comprises more than
5000 species of parasitic protozoa, which have a wide range
of vertebrate hosts. These pathogens have complex life cycles
with several developmental stages. Most protozoa of this
phylum are obligate intracellular parasites, for which host-
cell invasion is a vital requirement. Even though apicom-
plexan parasites diﬀer considerably in the type of host-cells
they can infect, which include erythrocytes, lymphocytes,
macrophages and even cells of the digestive tract from
diﬀerent animal species, they share conserved mechanisms
of invasion and motility. Many aspects of invasion in
Apicomplexa have thoroughly been reviewed elsewhere [9,
10, 77]. With the exception of Theileria, whose sporozoite
and merozoite stages are not motile [78], most members
of the phylum share a substrate-dependent locomotion
called gliding. This locomotion requires the coordinated
action of a multiprotein complex termed glideosome [79].
The glideosome is composed of adhesive proteins located
between the parasite’s plasma membrane (PM) and a pair of
membranes known as the inner membrane complex (IMC).
This type of motility is fundamental for cell invasion and
tissue colonization [9, 80, 81].
For invasion to take place, most apicomplexan parasites
must release the content of their specialized apical secretory
organelles (micronemes and rhoptries) [82]. After binding
to the host-cell, the parasite forms a ring-like structure
termed moving junction (MJ) between its apical tip and the
host-cell membrane [9]. The MJ is the result of the inter-
actions between mainly two well-conserved apicomplexan
proteins: AMA1 (apical membrane antigen 1) and RON2
(rhoptry neck protein 2) [11]. Subsequent penetration and
migration of the MJ is characterized by the formation of
a parasitophorous vacuole (PV) around the parasite [83]
that accommodates the invading zoite within the host cell.
This specialized vacuole, however, is not always conserved
throughout the intracellular parasite stage; the exceptions
being Babesia bovis [84] and Theileria spp [78], which escape
the PV once infection of the host-cell has been established.
The fate of the parasite in the host cell is, therefore largely
dependent on its ability to actively invade a cell by an MJ-
dependent process.
4. ProteinPalmitoylation, Invasion, andGliding
in Apicomplexa
The potential of apicomplexan parasites to colonize cells
or tissues depends directly on their capability to move,
adhere to, and invade the host cell in order to replicate
within it and thus, ensuring the survival of the pathogen.
Throughout the last decades, much eﬀort has been dedicated
to elucidate the intricate mechanisms underlying motility
and invasion of these parasites. The increasing expansion of
the knowledge of these peculiar eukaryotes allowed us to get
a better understanding of their biology, yet new questions
continuously arise. Ahead lies the study of the architecture
of some these protein complexes, how they assemble, how
each of their components get to their site of action, and how
they act in such concerted way. One possibility that might
shed light on these inquiries is the study of posttranslational
modifications, in particular protein palmitoylation.
The first report of protein palmitoylation in Apicomplexa
was performed on E. tenella where the protein cGMP-
dependent kinase (PKG) was shown to be palmitoylated
[25] and to be the target of the broad-spectrum coccidio-
stat 4-[2-(4-fluorophenyl)-5-(1-methylpiperidine-4-yl)-1H-
pyrrol-3-yl] pyridine. Interestingly, this compound was
eﬀective against coccidiosis in poultry and toxoplasmosis
in a murine model [85, 86]. Later studies on this modi-
fication came from the model organisms Plasmodium and
Toxoplasma [27, 30, 87, 88]. Recently, our group reported an
in silico analysis performed on T. gondii proteins suggesting
that many proteins involved in gliding and invasion may
be palmitoylated and proposing the existence of at least
17 possible PATs [30]. Experimental support was further
provided by a subsequent work that highlights the functional
importance of protein palmitoylation on three processes that
are crucial for the parasite’s life cycle and, therefore, for
its pathogenesis: gliding, invasion, and replication [87]. It
was observed that 2-bromopalmitate—a nonselective lipid
electrophile with selectivity towards reactive thiols widely
used to study protein palmitoylation [89, 90]—decreased the
invasive capacity of drug-treated tachyzoites. Even though
the invasion process is somehow altered, the initial attach-
ment to the host cell is not aﬀected. Our in silico analysis
allowed us to predict that two vital components of the
MJ might be palmitoylated: AMA1 and RON2. Moreover,
according to this study another micronemal protein with
roles in invasion and virulence, MIC2 [91], may also be
palmitoylated. Consequently, it is reasonable to infer that
protein palmitoylation could play a relevant role in MJ
assembly or in targeting its protein components to the cell
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membrane, enabling proper function of such relevant appa-
ratus for invasion. Since 2-bromopalmitate exerts pleiotropic
eﬀects on cellular metabolism, a thorough study on the
role of palmitoylation on these putative targets should be
performed.
Recently, antigen mapping made on another member
of the phylum, Eimeria maxima, identified a novel antigen:
IMP-1 (immuno mapped protein-1). This protein shares
features with AMA1 and, as such, can potentially induce
the same immunoprotection [92]. Further in silico analysis
showed the absence of a signal peptide or recognizable
domain in IMP-1. Additionally, the homologous counter-
parts in T. gondii (XM 002370108) and Neospora caninum
(NCLIV 000430) were found [92]. The latter was recently
characterized by Cui and colleagues [93], who reported that
palmitoylation and myristoylation operate on the protein,
targeting it to the parasite’s pellicle. Furthermore, the study
stated that antibodies against NcIMP-1 inhibit parasite
invasion, suggesting a role of this protein in invasion. The
same group isolated the protein from T. gondii and localized
it to the pellicle of the tachyzoite [94]. In addition, they
propose TgIMP-1 as a possible vaccine candidate since the
recombinant version of the protein stimulates both humoral
and cell-mediated immunity [93].
As mentioned above, invasion is associated to gliding
motility and, therefore, dependent on its glideosome. The
protein GAP45, an essential component of the glideosome,
has been shown to be palmitoylated in P. falciparum [26]
and predicted to be palmitoylated in T. gondii [30, 81]. This
protein appears to be essential to maintain pellicle cohesion
during the invasion process, thus membrane anchoring
through lipidic posttranslational modifications should play
a crucial role. In fact, it was reported that while N-terminal
myristoylation and palmitoylation anchors TgGAP45 to
the PM, palmitoylation on its C-terminal end allows its
interaction with the IMC [81].
Polonais et al. [88] postulated that another T. gondii
protein, myosin light chain 2 (MLC2), would have three
palmitoylation sites in its N-terminal region, and that this
region would be essential for membrane targeting. Fur-
thermore, MLC2 interacts with variant D of myosin heavy
chain (MyoD) which is also predicted to be palmitoylated,
suggesting that such acylation would allow the interaction
of proteins to form the complex MLC2-MyoD, which is
part of the actin-myosin motor that accounts for the power
necessary for parasite motility.
Tachyzoites treated with 2-bromopalmitate showed that
their motility pattern was seriously altered [87]. Proteins that
are part of the inner membrane complex (IMC) and the
glideosome are predicted to be palmitoylated according to
“in silico” analysis [30, 81, 88, 95], and this could explain
the observed phenomena. It is also worth noting that in T.
gondii parasites with reduced MIC2 expression—a putative
palmitoylated protein [30]—exhibit less helical gliding [91].
Nowadays the question regarding the role of lipid mod-
ifications on these proteins still remains unsolved. Lipid
modifications might be important for the correct assembly
of multiprotein complexes or to allow synchronicity of the
gliding, or perhaps they are involved in protein transport
from their origin to their site of action.
5. Protein Palmitoylation and Cell Shape
Besides maintaining cell shape, the cytoskeleton provides
essential support for vital functions such as cell motility
and replication. In Toxoplasma, the glideosome is composed
of myosin A, a myosin light chain 1 (MLC1) and gliding-
associated proteins 40, 55, and 50 [96, 97]. As such,
the IMC functions as a platform for the actin-myosin
apparatus required for host-cell invasion and, together with
subpellicular microtubules are important during replication
as well. In addition, these subpellicular microtubules are also
important for organelle replication, polarity, elongated cell-
shape, and for driving cell division [98, 99]. A complete
review on cell-cycle, cytokinesis, and the structures that
take part in them can be found elsewhere [14, 15, 100].
Cell division in apicomplexa involves DNA replication and
chromosome segregation, nuclear division, and cytokinesis.
The intracellular stages of apicomplexan parasites are quite
diverse, and this diversity lies in the flexibility of the
apicomplexan mode of replication. Whereas Toxoplasma
divides through a mechanism termed endodyogeny, wherein
two parasites are assembled within a mother cell giving
2, 4, 8, and so forth tachyzoites per vacuole after several
rounds of replication, Plasmodium and Sarcocystis dispense
with cytokinesis and/or nuclear divisions for multiple cycles,
forming a single multinucleate cell [15]. In Toxoplasma,
daughter cells are encapsulated by the IMC and assembled
by the cortical cytoskeleton (subpellicular microtubules and
intermediate-filament like proteins) [101–106]. The apical
polar ring microtubule-organizing center (MTOC) drives
Toxoplasma budding [100], whereas the nuclear segregation
is coordinated by the centrocone [107]. Therefore, both
processes are separate events allowing disconnection of
nuclear division and/from budding [100].
Long-term treatment of T. gondii intracellular tachyzoites
with 2-bromopalmitate results in major changes in parasite
morphology and shape [87]. Interestingly, this eﬀect could
only be observed in mature intracellular parasites but not in
budding cells. Furthermore, treatment of either extracellular
tachyzoites or tachyzoites that recently invaded cells did not
show any change in their morphology. Consequently, palmi-
toylation seems to be important to maintain the morphology
of the mature intracellular tachyzoite after the first round of
replication, may be by palmitoylation of some cytoskeletal
proteins. Thus, this posttranslational modification could be
important to maintain cell shape. TgMORN1 is a protein
associated to the cytoskeleton and to ring structures at the
apical and posterior end of the IMC and to the centrocone
[101]. This protein, which seems to play a role inmaintaining
the parasite’s integrity during cytokinesis [102], is predicted
to be palmitoylated. In 2010, Beck et al. [95] reported that
three putative palmitoylated proteins of T. gondii’s IMC—
IMC subcompartment proteins; TgISPs—were important for
daughter cell formation. Furthermore, actin-like protein 1
(ALP1; toxodb accession TGME49 019280) is important for
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IMC protein delivery to the bud and is also predicted to
be palmitoylated on cysteine residues 3 and 216. Two other
proteins that are predicted to be palmitoylated and that
may play a role in cytokinesis are striated fibre-assembling
(toxodb accession TGME49 005670) and centrin 4 (toxodb
accession TGME49 029910). In 2011, 14 new IMC proteins
were found by data mining [104]. Interestingly these proteins
showed diﬀerential expression during cytokinesis and most
of them are predicted to be palmitoylated either at their N-
or C-terminus.
The possibility of having diﬀerent PATs expressed at
diﬀerent regions of the mature IMC has been previously
discussed [95]. Thus, it is also possible that these PATs could
associate to the IMC at a later stage of parasite replication
or only in mature tachyzoites, regulating the final step of
parasite morphology.
6. Conclusions and Future Trends
Pathogenesis of diseases caused by apicomplexan parasites is
highly dependent on two events: invasion to and replication
within the host-cell. It is now clear that protein lipidation,
and in particular palmitoylation, actively participates in the
regulation of localization and function of proteins associated
to mechanisms that are essential for the pathogenesis of the
parasites.
To date, protein acylation in apicomplexans has been
studied through genetic engineering methods such as muta-
genesis or by in silico analysis, leaving aside more “classical”
biochemical methods. The use of an inhibitor can provide
evidence of the functional role of a modification in a
given system. Thus, the evidence obtained when parasites
were treated with 2-bromopalmitate representss the first
evidence that protein palmitoylation in Apicomplexa aﬀects
parasite physiology [87]. For the next years, the eﬀorts
should focus on elucidating the palmitoyl proteome of
apicomplexan parasites and the underlying mechanism of
palmitoylation in apicomplexan pathogenesis. In this sense,
in the recent years new approaches have been developed
for characterizing protein palmitoylation. These approaches
are more sensitive and faster than the traditional labeling,
providing new opportunities for exploring this posttrans-
lational modification. Bioorthogonal ligation reactions and
azide-alkyne cycloadditions [108], palmitic acid analog 17-
octadecynoic acid (17-ODYA; [109]), and chemical reporters
combined with orthogonal clickable fluorophores [110]
are some of the new approaches that will shed light
into the functional roles of lipidated proteins. The high
sensitivity and eﬃciency of these approaches should assist
the functional characterization of factors and drugs that
modulate protein palmitoylation. The application of these
biochemical methods together with proteomic tools and
molecular biology will provide the means to resolve the
palmitoyl-proteomes of model apicomplexans, as it has been
carried out for trypanosomatids [111].
The enzymes involved in both the addition and removal
of the palmitate residue are potential therapeutic targets for
the treatment of parasitic diseases. Hence, the use of all the
available tools will allow unraveling the molecular processes
underlying palmitoylation in unicellular organisms and will
shed light on the biology of these parasites.
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